Moderna received another $ 472 million to develop the COVID-19 vaccine

The company’s management expressed confidence in the successful completion of the work.

Moderna Inc said on Sunday that it received an additional $ 472 million from the office of higher biomedical research to develop a vaccine for the new coronavirus.

The US-based drug company explained that the additional funding is intended to help the company’s work in late-stage clinical trials.

In April, Moderna received 483 million from the Federal Agency that finances the development of medical technologies. This happened at a time when the event of an experimental vaccine was at an early stage – at the scene of trials conducted by the National Institutes of health.

If you have found a spelling error, please, notify us by selecting that text and pressing Ctrl+Enter.

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Author: Steve Cowan
Graduated From Princeton University. He has been at the Free Press since October 2014. Previously worked as a regional entertainment editor.
Function: Chief-Editor
Steve Cowan

Spelling error report

The following text will be sent to our editors:

37 number 0.260931 time